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Glycogenolytic and antiglycogenolytic prostaglandin E, actions in rat hepatocytes
Prostaglandin E, has been reported both to stimulate glycogen-phosphorylase activity (glycogenolytic effect) and to inhibit the glucagon-stimulated glycogen-phosphorylase activity (antiglycogenolytic effect) in rat hepatocytes. It was the purpose of this study to resolve this apparent contradiction and to characterize the signalling pathways and receptor subtypes involved in the opposing prostaglandin E, actions.
Prostaglandin E, (10 pM) increased glucose output, glycogen-phosphorylase activity and inositol trisphosphate formation in hepatocyte cell culture andor suspension. In the same systems, prostaglandin E, decreased the glucagon-stimulated (1 nM) glycogen-phosphorylase activity and cAMP formation.
The signalling pathway leading to the glycogenolytic effect of PGE, was interrupted by incubation of the hepatocytes with 4P-phorbol 12-myristate 13-acetate (100 nM) for 10 min, while the antiglycogenolytic effect of prostaglandin E, was not attenuated.
The signalling pathway leading to the antiglycogenolytic effect of prostaglandin E, was interrupted by an incubation of cultured hepatocytes with pertussis toxin (100 ng/ml) for 18 h, whereas the glycogenolytic effect of prostaglandin E, was enhanced.
The EP,/EP, prostaglandin-E,-receptor-specific prostaglandin E, analogue Sulproston had a stronger glycogenolytic potency than the EP, prostaglandin-E,-receptor-specific prostaglandin E, analogue Misoprostol. The antiglycogenolytic potency of both agonists was equal.
It is concluded that the glycogenolytic and the antiglycogenolytic effects of prostaglandin E, are mediated via different signalling pathways in hepatocytes possibly involving EP, and EP, prostaglandin E, receptors, respectively.
Prostaglandins have been implicated to participate in cell to cell signal propagation between non-parenchymal and parenchymal cells in the liver. They are synthesized only in non-parenchymal liver cells [ 11, primarily Kupffer cells, but also in endothelial cells and Ito cells. They are degraded mainly by the parenchymal cells, i.e. hepatocytes [2-61, which also have been shown to possess binding sites for prostaglandins [2, [7] [8] [9] [10] . The role of prostaglandins in the regulation of liver metabolism has been discussed controversially in previous studies. The use of cyclooxygenase inhibitors have revealed the involvement of prostaglandins in signalling pathways leading to an increase in glycogenolysis and glucose output elicited by such diverse stimuli as zymo- [27, 281. In addition, prostaglandins E, and F,, have been shown to decrease glucagon-stimulated glycogen-phosphorylase activity and cAMP formation in rat hepatocytes . These studies failed to show a stimulatory effect of prostaglandins on basal glycogen-phosphorylase activity and glucose output. The contradicting results have been ascribed to differences in the experimental protocol. It was the purpose of this study to resolve this apparent contradiction and to study the signalling pathways as well as the receptor subtypes involved in the glycogenolytic and antiglycogenolytic PGE, actions.
PGE, stimulated glycogen-phosphorylase activity both in cell suspension and cell culture (glycogenolytic effect). In the same experimental systems, PGE, decreased the glucagonstimulated glycogen-phosphorylase activity (antiglycogenolytic effect). The glycogenolytic effect was mediated via an InsP,-coupled PMA-inhibitable signal chain possibly involving EP, prostaglandin-E, receptors, whereas the antiglycogenolytic effect was mediated via a G,-(inhibitory G protein)-linked, pertussis-toxin-sensitive signal chain, possibly involving type 3 prostaglandin-E, receptors (EP,).
MATERIALS AND METHODS

Materials
All chemicals were reagent grade and were from commercial sources. The Merck Glucose System was purchased from Merck. Lactate dehydrogenase, alanine amino transferase, M199 and fetal calf serum were from Boehringer. PGE, was from Paesel; the InsP, and cAMP assay kit was from Amersham Buchler. Percoll was purchased from Pharmacia. Misoprostol and SC 19220 were gifts of Searle; Sulproston and AH 6809 were gifts of Schering and Glaxo, respectively.
Methods
Male Wistar rats (160-200 g, Winkelmann) were kept on a 12-h dayhight rhythm, light from 7 a.m. to 7 p.m., with free access to water and food (standard rat diet, Ssniff). All experiments were begun between 9 a.m. and 10 a.m. Rats were anaesthetized by intraperitoneal injection of pentobarbital (60 mgkg body mass).
For cell-suspension experiments, hepatocytes were isolated according to Meredith without the use of collagenase [39] to avoid degradation of surface receptors by the proteases during cell preparation. The method was slightly modified. The liver was perfused without recirculation via the portal vein with a Ca2+-free Krebs-Henseleit buffer containing 15 mM glucose, 2 mM lactic acid, 0.2 mM sodium pyruvate and 2 mM EDTA for 30-40 min. [40] or as described above for cell suspensions according to Meredith [39] . Both methods yielded the same results. Hepatocytes were plated on 9-cm2 tissue plates (9 mg/plate, 9X105 cells/plate) in M199 medium containing 0.5 nM insulin, 100 nM dexamethasone, penicillin/streptomycin (10 mg/ml) and for the first 4 h of culture 4% fetal calf serum. After 24 h in primary culture, the medium was removed and cells were washed three times with buffer A. Cells were incubated for 10 min at 37°C in 1 ml buffer A; then PGE, (final concentration The student's t-test for paired values was performed. a, P < 0.01 ; b, P < 0.05. 10 pM), glucagon (1 nM) or both were added. The buffer was removed after 2 min and the plates were frozen in liquid nitrogen.
Glucose was assayed in the hepatocyte supernatants using a commercial test kit (Merck Glucose System) based on the glucose-dehydrogenase method [41] . Lactate was measured using a combined optical test with alanine amino transferase and lactate dehydrogenase in a glutamate buffer (230 mM glutamate, pH 9.5) [42] . Glycogen-phosphorylase activity was determined by a standard assay [43] and protein was determined by the method of Lowry [44] ; InsP, and cAMP were determined using Amersham radioligand assays.
RESULTS
Glycogenolytic and antiglycogenolytic effect of PGE, in hepatocyte suspensions and hepatocyte cultures
Hepatocytes were suspended in Hepes-buffered saline. After a 1 0-min incubation at 37"C, the glucose concentration was approximately 5 mM. At this time, buffer (controls), PGEZ, glucagon or PGE, plus glucagon were added. Cells released glucose at a basal rate of 0.78 t0.08 pmol . min-'
. g-', the basal glycogen-phosphorylase activity was 4.6 pmol . min-' . g cells-', the basal InsP, level was 0.9 5 0.2 nmol . g cells-'. PGE, enhanced glucose output by 20%, glycogen-phosphorylase activity by 60% and InsP, levels by approximately 100% (Fig. 1 left, Table 1 ). Glucagon increased glucose output by 50% and glycogen-phosphorylase activity by 160%. Glucagon stimulated hepatocytes to take up lactate at a rate of 0.31 pmol . rnin ' . g-I. It had no Table 1 . Increase in glucose output and lactate uptake by PGE,, glucagon and PGE, plus glucagon. Rat hepatocytes (30 mg in a final volume of 1 ml), that were prepared as described in the Materials and Methods section, were incubated at 37°C in Hepes-buffered saline, containing approximately 5 mM glucose at the beginning of the experiment. PGE,, glucagon or both were added to a final concentration of 10 pM and 1 nM, respectively. Glucose and lactate were determined in the supernatant at 1 effect on InsP, formation. The glucagon-mediated increases in glucose output, lactate uptake and glycogen-phosphorylase activity were partially inhibited, if PGE, was added concomitantly with glucagon ( Fig. 1 left, Table 1 ). InsP, formation was not significantly different from samples that were stimulated with PGE, alone. Similar results were obtained in hepatocytes after 24 h of primary culture, yet changes in metabolite concentrations could not be determined because of the unfavourable ratio of cell mass to medium. PGE, as well as glucagon increased the glycogen-phosphorylase activity by 50% and 1 SO%, respectively (Fig. 2 ). Glucagon increased the cAMP level by more than 1000% (from 0.2 to 2.4nmol/g) but PGE, had no effect. Both the glucagon-mediated increase in glycogenphosphorylase activity and cAMP formation were antagonized if PGE, was administered simultaneously with glucagon ; the glucagon-stimulated glycogen-phosphorylase activity was lowered to the same activity as with PGE, alone, the cAMP level was reduced strongly (Fig. 2 left) .
Interruption by 4P-phorbol 12-myristate 13-acetate of the glycogenolytic but not the antiglycogenolytic PGE, signal chain Activation of protein kinase C with the phorbol ester 4p-phorbol 12-myristate 13-acetate (PMA) has been shown to interrupt the signal chains of hormones, that mediate their effects via an increase in InsP, and cytosolic free calcium, e.g. noradrenaline or vasopressin [45 -491. Incubation of hepatocytes in suspension for 10 min prior to the experiment with 100 nM PMA, which suffices to activate protein kinase C [45] , resulted in a partial reduction of the PGE,-mediated increase in glycogen-phosphorylase activity and an almost complete reduction in PGE,-mediated InsP, formation (Fig. 1  right) . The glucagon-mediated increase in glycogen-phosphorylase activity was not affected by a prior PMA treat- 
Interruption by pertussis toxin of the antiglycogenolytic but not the glycogenolytic PGE, signal chain
The signal chain leading to the antiglycogenolytic PGE, effects had previously been shown to be interrupted by prior treatment of hepatocytes with pertussis toxin [32, 341. As in these studies, treatment of hepatocytes in primary culture with 100 ng/ml pertussis toxin for 18 h abolished the inhibitory effect of PGE, on the glucagon-stimulated glycogenphosphorylase activity (Fig. 2) . The glucagon-mediated increase in cAMP formation, that had been inhibited strongly by PGE2, was partially restored in cells that had been incubated with pertussis toxin for 18 h prior to the experiment; cAMP levels increased by 350% (from 0.2-0.85 nmol/g) and thus reached approximately 35% of the level of glucagon-stimulated cells. In contrast to the antiglycogenolytic PGE, effect, the glycogenolytic PGE, effect was not inhibited but rather enhanced by a pertussis toxin treatment ; the PGE,-mediated increase in glycogen-phosphorylase activity was twice as large as in control cells. In cells treated with pertussis toxin, PGE, caused a small but significant increase in cAMP formation by 50% (from 0.2-0.3 nmol/g). Hepatocytes were maintained in primary culture for 24 h in M199 containing 0.5 nM insulin, 100 nM dexamethasone and 1 % (mass/ vol.) penicillin-streptomycin on 3-cm-diameter tissue-culture plates. For the experiments, cells were washed three times with Hepesbuffered saline, containing 5 mM glucose, 2 mM lactate and 0.2 mM pyruvate. 1 ml of this buffer was added to all plates. After 10 min, PGEz at the concentration indicated and glucagon (1 nM) were added simultaneously. The reaction was stopped after 2 min by removing the medium and freezing the plates in liquid nitrogen for a later determination of the cAMP concentration in a radioimmunoassay. Values are the means i SEM of four experiments.
Concentration dependence of the glycogenolytic and antiglycogenolytic PGE, response
PGEz stimulated glycogen-phosphorylase activity half maximally at concentrations of approximately 0.5 pM (Fig. 3) . It also increased InsP, significantly at concentrations greater than 1 pM PGE, (data not shown); a dosehesponse curve for the formation of InsP, could, however, not be obtained since the results varied too much between the experiments (compare Fig. 1 ). PGE, inhibited the glucagondependent increase in glycogen-phosphorylase activity (data not shown) and in the increase cAMP (Fig. 4) at concentrations of 0.1-50 pM. Since the inhibitory PGE, effect was clearly greater with cAMP formation (compare Fig. 2) , the latter was the better parameter to obtain a dose/response curve (Fig. 4) . The glucagon-stimulated cAMP formation was half-maximally inhibited at PGE, concentrations of approximately 0.2 pM. The dose/response curves do not allow to distinguish whether a single or different subtypes of the PGE, receptor were involved in the glycogenolytic and the antiglycogenolytic PGE, action, because both effects were half maximal at similar concentrations and because the saturation level for the signal chains is not known.
Receptors involved in the glycogenolytic and the antiglycogenolytic PGE, actions
So far, three types of PGE, receptors, named EP,, EP, and EP, receptors, have been described in non-hepatic organs [50, 511. To assess whether a single PGE, receptor type was linked to two different signal chains or whether two different PGE, receptor types were responsible for the glycogenolytic and the antiglycogenolytic PGE, effects, experiments with the EP,/EP, receptor-specific agonist Sulproston and the EP,-specific Misoprostol were performed. Both agonists are approximately equipotent on EP, receptors [52] . In addition, Sulproston potently stimulates EP, receptors and EP, receptors in chick ileum [50, 511. Misoprostol is equipotent with PGE, on guinea pig vas deferens EP, receptors and is three times less potent on EP, receptors of cat trachea [53] .
Both Sulproston and Misoprostol stimulated glycogenphosphorylase activity (Fig. 5 ) , yet the EP, and EP, agonist Sulproston enhanced glycogen phosphorylase activiy at 10 pM concentrations approximately twice as much as the EP, agonist Misoprostol. The half-maximally effective concentration (EC,,) of Sulproston for the stimulation of glycogen phosphorylase was approximately tenfold lower than the EC,, of Misoprostol. At concentrations that half-maximally stimulated glycogen-phosphorylase activity, Sulproston (0.5 pM) and Misoprostol (3 pM) increased the InsP, formation to 152 % 28% and 166 2 17%, respectively. Neither Sulproston nor Misoprostol at concentrations up to 50 pM increased cAMP formation. Thus, the glycogenolytic effect was probably mediated via EP, receptors. Sulproston and Misoprostol also inhibited the glucagonstimulated cAMP formation with a similar EC,, value of approximately 0.1 pM (Fig. 6 ). Since both substances can act as EP, agonists, the antiglycogenolytic effect was most likely mediated via EP, receptors. To further corroborate these data, the EP,-receptor-selective antagonists AH 6809 and SC 19220 were used. However, AH 6809 had a strong intrinsic activity; it stimulated glycogen-phosphorylase activity twofold over basal rates and had no antiglycogenolytic effect on the glucagon-stimulated glycogen-phosphorylase activity (data not shown). SC 19220 neither inhibited the glycogenolytic nor the antiglycogenolytic PGE, effect if added at concentrations up to approximately 10 pM as a stock solution in ethanol (data not shown). Since this drug is extremely insoluble in water and the addition of higher concentrations of organic solvents is prohibitive in cell-suspension experiments, the effective concentration of SC 19220 might have been much lower. Thus, the lack of an inhibition by this inhibitor does not argue against the involvement of EP, receptors.
DISCUSSION
Glycogenolytic and antiglycogenolytic PGE, actions in the same experimental system
The glycogenolytic and antiglycogenolytic actions of PGE, have previously been observed in different experimental systems. The glycogenolytic effect has either been shown in rat liver perfused with glucose-free [23, 25, 261 or glucose-containing medium [24] or in hepatocyte suspensions with glucose-free media [27, 281. In these investigations, an increase either in glucose output or glycogen-phosphorylase . In these studies, either the glycogenolytic rate was determined as the release into the medium of glucose or
[14C]glucose from labelled glycogen, or the decrease in the glucagon-induced cAMP formation was measured. Differences in the experimental set up, i.e. perfusion and cell suspension with glucose-free media versus culture with glucosecontaining media have previously been used [37] to explain the lack of glycogenolytic PGE, effects in the latter studies with cultures . A slight PGE,-mediated increase in cAMP has previously been described in hepatocytes in the presence of the CAMP-phosphodiesterase inhibitor isobutyl methyl xanthine together with an inhibition of the glucagonmediated cAMP formation [32] . A potentiation of the glucagon-mediated glucose output at low (1 0-' M) concentrations of PGE, and an attenuation of the glucagon-mediated glucose output at high (10-'M) concentrations of PGE, in cell suspension in a glucose-free and lactate free medium has also been reported [28] .
In the present investigation, both the glycogenolytic and antiglycogenolytic actions of PGE, have been observed in hepatocyte suspensions and cultures with media containing 5 mM glucose, 2 mM lactate and 0.2 mM pyruvate by measuring glycogen-phosphorylase activity. Moreover, in suspensions an increase by PGE, in basal glucose release and a decrease by PGE, in the glucagon-stimulated glucose release into the medium could be demonstrated. In addition to the attenuation of the glucagon-stimulated glycogenolysis, PGE, seemed to decrease the glucose output from the hepatocytes by diminishing the glucagon-stimulated lactate uptake, which can be used as a rough estimate for gluconeogenesis. Both the glycogenolytic and antiglycogenolytic PGE, effects were half maximal at concentrations of 0.5 pM exceeding by at least one order of magnitude the systemic or portal concentrations of 0.5-1 nM. However, local prostaglandin concentrations of 5-10 pM may be reached in the proximity of hepatocytes due to the local production and secretion into the narrow space of Disse by non-parenchymal liver cells [lo] .
Involvement of different signal chains
The glycogenolytic PGE, effect was mediated via an InsP,-dependent signal chain. It could be interrupted by a short-term activation of protein kinase C with the phorbol ester PMA (Fig. 7, compare Fig. 1 ). This interruption by PMA has been demonstrated previously for other InsP,-dependent signal chains such as noradrenaline, vasopressin, phenylephrine [45 -491 and prostaglandins [54-561 . Activation of protein kinase C neither interfered with the CAMPdependent signal chain of glucagon nor with the antiglycogenolytic PGE, signal chain.
The antiglycogenolytic PGE, effect was mediated via a decrease in CAMP. It could be inhibited by an incubation of hepatocytes with pertussis toxin (Fig. 7, compare Fig. 2 ). This is in agreement with previously published data [32, 341 . By contrast, the glycogenolytic PGE, effect was rather enhanced. Thus, the antiglycogenolytic effect but not the glycogenolytic effect was mediated via a pertussis-toxin-inhibitable G, protein.
Treatment with pertussis toxin abolished the inhibition by PGE, of the glucagon-stimulated glycogen-phosphorylase activity entirely, whereas it reduced the inhibition by PGE, of the glucagon-stimulated cAMP formation only partially. Hence, a submaximal increase (35%) in cAMP formation already yielded a maximal activation of glycogen phosphorylase. This lack of a strict correlation of cAMP formation and activation of glycogen phosphorylase, where cAMP apparently is produced in excess, is a well-known phenomenon [57, 581 which is also observed with the second messenger InsP, [59] .
The enhancement of the glycogenolytic PGE, effect by pertussis toxin might be explained in two ways. (a) Pertussis toxin might have diminished an inhibition by PGE, of the glycogenolytic of the phospholipase-C-linked PGE, signal chain. This inhibition might be mediated via a pertussis toxin sensitive phospholipase-C-like G, protein as has been described for endothelin in brain [60] and heart [61] . This hypothesis cannot be tested at the level of the second-messenger InsP,, since the increases in InsP, formation seems not to correlate strictly with the activation of glycogen phosphorylase [27, 591. (b) Alternatively, pertussis toxin might abrogate a PGE,-enhanced block via a G, protein of a stimulatory G-protein (GJ-linked glycogenolytic PGE, signal chain. The latter view is supported by the fact that PGE, elicited a small but significant increase in cAMP formation only in presence of pertussis toxin (Fig. 2) indicating that the partial inactivation of a G, protein revealed the presence a G,-linked PGE, receptor signal chain normally obscured by the predominance of G, action. This is in agreement with a previous finding, that a small PGE,-mediated increase in cAMP formation was potentiated by initial treatment of hepatocytes with pertussis toxin [32] .
Involvement of different receptor types
PGE, receptors have been subdivided into three classes, EPI, EP, and EP, receptors [SO, 511, according to the relative potency of PGE, analogues in various non-hepatic tissues and the signal chain they use. The existence of a fourth EPreceptor subtype linked to G, has been suggested [62] and two isoforms of the EP, receptor have been cloned [63] . Receptors designated EP, receptors operate via phospholipase C and InsP, [64] , EP, receptors via a G,-mediated increase in cAMP and EP, receptors via a GI-mediated decrease in cAMP [65] . Since the glycogenolytic effect of PGE, could be mimicked best by Sulproston, that acts both as an EP, and EP, agonist, whereas the EP,-selective Misoprostol was clearly less effective, it seems that the glycogenolytic effect of PGE, was mediated via EP, receptors (Fig. 7, compare  Fig. 5 ). This is in agreement with the observed increase in InsP, (Fig. 1) .
The antiglycogenolytic PGE, effect was mimicked equally well by Sulproston and Misoprostol, which have a similar affinity to EP, receptors [52] . The antiglycogenolytic PGE, effect thus seems to be mediated by EP, receptors (Fig. 7, compare Fig. 6 ). This is in agreement with the observed pertussis-toxin-sensitive decrease in cAMP formation (Fig. 2) .
Conclusion
The data presented in this study favour the hypothesis that hepatocytes possess two PGE, receptor subtypes. These subtypes are an EP, receptor that stimulates glycogenolysis via a PMA-sensitive, pertussis-toxin-insensitive InsP,-linked signal chain and an EP, receptor that inhibits the glucagonstimulated glycogenolysis via a pertussis-toxin-sensitive G, protein.
